Monitorização biológica por método citogenético em indivíduos expostos profissionalmente a agentes antineoplásicos
DOI:
https://doi.org/10.32635/2176-9745.RBC.1991v37n1/4.3097Palabras clave:
Agentes Antineoplásicos, Quimioterapia, Risco Ocupacional, Aberrações Cromossômicas, Trocas Entre Cromátides-IrmãsResumen
Enfermeiras, atendentes e assistentes de enfermagem que preparam e aplicam antineoplásicos em unidades hospitalares apresentaram freqüências aumentadas de anomalias e de trocas entre cromátides-irmãs (TCI) em cromossomos de linfócitos periféricos. Não foi detectada associação entre as freqüências desses fenômenos e os tipos de dispositivos de proteção ou o tempo de exposição aos antineoplásicos, possivelmente devido à multiplicidade de variáveis atuantes, o que dificultou a interpretação do papel de fatores isolados. No entanto, foi detectada uma associação entre o grau de escolaridade e a freqüência de anomalias citogenéticas, que é menor nos profissionais de nível superior que naqueles com formação técnica ou prática. Além disso, a freqüência de anomalias cromossômicas e de TCI foram menores quando as profissionais expostas manuseavam menos freqüentemente os antineoplásicos mais tóxicos. A amostra de aplicadores de antineoplásicos analisada, portanto, pertence a um grupo de risco para a ocorrência de lesões no material genético, indicando a necessidade de que sejam sempre observadas as normas de segurança previstas para o manuseio desses compostos e sugerindo a conveniência da monitorização biológica periódica nos indivíduos a eles profissionalmente expostos.
Descargas
Citas
LEVANTINE A, ALMEYDA J. cutaneous reactions to cytostatic agents. BrJ Dermatol 1974; 90: 239-242. DOI: https://doi.org/10.1111/j.1365-2133.1974.tb06396.x
STEPHENS LC, WANG YM, SCHULTHEISS TE, JARDINE JH. Enhanced cardiotoxicity in rabbits treated with verapamil and adriamycin. Oncology 1987; 44: 302-306. DOI: https://doi.org/10.1159/000226499
MULDER POM, SLEIJFER DT, de VAIES EGE, UGES DRA, MULDER NH. Renal dysfunction following high-dose carboplatin treatment. J Cancer Res Clin Oncol 1988; 114: 212-214. DOI: https://doi.org/10.1007/BF00417840
RUCCIONE K, WEINBERG K. Late effects in multiple body systems. Semin Oncol Nurs 1989; 5(1): 4-13. DOI: https://doi.org/10.1016/0749-2081(89)90017-X
SZNOL M, OHNUMA T, HOLLAND JF. Hepatic toxicity of drugs used for hematologic neoplasia. Sem Liv Dis 1987; 7(3): 237-256. DOI: https://doi.org/10.1055/s-2008-1040580
NEWMAN CE, ELLIS DJ. Pancreatitis during combination chemotherapy. Clin Oncol 1979; 5:83-84.
UR BA S, FORASTI ERE AA. Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer. Cancer 1988; 62: 2094-2097. DOI: https://doi.org/10.1002/1097-0142(19881115)62:10<2094::AID-CNCR2820621004>3.0.CO;2-Q
BYRNE J, MULUIHILL JJ, MYERRS MH, CONNELLY AR, NAUGHTON MD, KRAUSS MR, STEINHORN sc, HASSINGER DO, AUSTIN DF, BRAGG K, HOLMES GF, HOLMES FF, LATOURETTE HB, WEYER PJ, MEIGS JW, TETA MJ, COOK JW, STRONG LC. Effects of treatment on fertility in Iong-term survivors of childhood or adolescent cancer. New England J Med 1987; 317(21): 1315-1321. DOI: https://doi.org/10.1056/NEJM198711193172104
SCHELEUNING M, CLEMM C. Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. New England J Med 1987; 317(26): 6666-6667. DOI: https://doi.org/10.1056/NEJM198712243172614
BERGER MR, PETRU E, SCHAMAHL O. Carcinogenicity of 1-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroenthyl)-3-nitrosourea-hydrochloride and three related N-nitroso derivatives following repeated intra-venous administration to male wistar rats. Oncology 1988; 45: 127-133. DOI: https://doi.org/10.1159/000226546
ZACCARIA A, ALIMENA G, BACCARANI M, BILLSTROM A, CARBONELL F, CASTOLDI GL, FUSCALDO HECHT F, HOSSFELD OK, MITELMAN F, ROSTI G, SANDBERG AA, TASSINARI A, TESTONI N, TARA S. Cytogenetic analyses in 89 patients with secondary hematologic disorders - Results of a cooperative study. Cancer GenetCytogenet 1987; 26:65-74. DOI: https://doi.org/10.1016/0165-4608(87)90134-8
SIEBER SM, ADAMSON AH. Toxicity of antineoplastic agents in man: chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential. Cancer Res 1975; 22: 57-155. DOI: https://doi.org/10.1016/S0065-230X(08)60176-1
MONDELLO S, GIORGI R, NUZZO F. Chromosomal effects of methotrexate on cultured human Iymphocytes. Mutat Res 1984; 139: 67-70. DOI: https://doi.org/10.1016/0165-7992(84)90105-2
SINGH B, GUPTA AS. Mutagenic responses of thirteen anticâncer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in chinese hamster ovary cells. Cancer Res 1988; 577-584.
ZHANG 5, HUANG JH, CHEN PL, LI CH. Sister chromatid exchanges and ceil cycle patterns of normal human bone marrow cells after in vitro exposure to cytostatic drugs. Cancer Genet Cytogenet 1988; 31: 157-163. DOI: https://doi.org/10.1016/0165-4608(88)90211-7
ABRAHAM SK, FRANZ J. Induction of sister-chromatid exchanges by chemotherapeutic drugs in spermatogonia of mice: effects of procarbazine, adriamycin, cyclofosphamide and mitomycin. C Mutat Res 1983; 108: 373-381. DOI: https://doi.org/10.1016/0027-5107(83)90133-1
LAMBERT B, RINGBORG U, HARPER E, LINDBLAD A. Sister-chromatid exchanges in lymphocyte cultures of patients receiving chemotherapy for malignant disorders. Cancer Treat Rep 1978; 62(10): 1413-1419.
GEBHART E. Chromosomal aberrations in Iymphocytes of patients under chemotherapy. In: Obe G ed. Mutations in Man. Berlin Springer-Verlag 1984: 198-223. DOI: https://doi.org/10.1007/978-3-642-69530-8_10
MURTY VVVS, MITRA AB, SHARMA A, DAS BC, LUTHRA UK. Mitomycin C induced chromosomal aberrations and sister chromatid exchanges (SCEs) in lymphocytes of patients with precancerous and cancerous lesions of the uterine ceriix. Neoplasma 1987; 34(1): 101-105.
LADIK CF, STOEHR GP, MAU RER MA. Precautionary measures in the preparation of antineoplastic. Am J Hosp Pharm 1980; 37: 1184-1186. DOI: https://doi.org/10.1093/ajhp/37.9.1184
REYNOLDS RD, LAWRENCE IR. Adverse reactions to AMSA in medical personnel. Cancer Treat Rep 1982; 66: 1885.
SOTANIEME EA, SUTINEN S, ARRANTO AJ. Liver damage in nurses handling cytostatic agents. Acta Med Scand 1983; 214: 181-189. DOI: https://doi.org/10.1111/j.0954-6820.1983.tb08593.x
McDIARMID H, EGAN T. Acute occupational exposure to antineoplastic agents. J Occup Med 1988; 30(12): 984-987. DOI: https://doi.org/10.1097/00043764-198812000-00020
HIRST M, TSE S, MILLS DG, LEVINE L, WHITE DF. Caution on handling antineoplastic drugs. New England J Med 1983; 309: 188-189. DOI: https://doi.org/10.1056/NEJM198307213090319
JAGUN O, RYAN M, WALDRON HA. Urinary tioether excretion in nurses handling citotoxic drugs. Lancet 1982; 443-444. DOI: https://doi.org/10.1016/S0140-6736(82)90474-3
KORENBERG JR, FREEDLENDER EF. Giemsa Technique for the detection of sister chromatid exchanges. Chromosoma 1974; 48: 355-360. DOI: https://doi.org/10.1007/BF00290992
ISCN (1978). An International system for human cytogenetic nomenclature (1978). Cytogenet Ceil Gonet 1978; 21:309-404. DOI: https://doi.org/10.1159/000130909
STAINO N, DGALLELLI JF, ADAMSON RH, THORGEIRSSON SS. Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. Lancet 1981; 1(8220): 615-616. DOI: https://doi.org/10.1016/S0140-6736(81)92064-X
GIBSON JF, GOMPERTZ D, HEDWORTH-WHITTY RB. Mutagenicity of urine from nurses handling cytotoxic drugs. Lancet 1984; (6923): 100-101. DOI: https://doi.org/10.1016/S0140-6736(84)90024-2
BARALE R, SOZZI G, TONIOLO P, BORGHI O, REALI D, LOPRIENO N, PORTA GD. Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytostatic drugs. Mutat Res 1985; 157: 235-240. DOI: https://doi.org/10.1016/0165-1218(85)90121-1
POYEN D, De MEO MP, BOTTA A, GOUVERNETJ, DUMÉNIL G. Handling of cytostatic drugs and urine mutagenesis. Int Arch Occup Environ Health 1988; 61: 183-188. DOI: https://doi.org/10.1007/BF00381017
FALCK K, GROHN P, SORSA M, VAINIO H, HEINONER E, HOLSTI L. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1(8128): 1250-1251. DOI: https://doi.org/10.1016/S0140-6736(79)91939-1
BOS RP, LEENAARS AO, THEUWS JLG, HENDERSON PTh. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health 1982; 50: 359-369. DOI: https://doi.org/10.1007/BF00377832
BENHAMOU S, CALLAIS F, SANCHO-GARNIER H, MIN S, COURTOIS YA, FESTY B. Mutagenicity in urine from nurses handling cytostatic agents. Eur J Cancer CUn Oncol 1986; 22(1 2): 1489-1493. DOI: https://doi.org/10.1016/0277-5379(86)90085-4
POHLOVÁ H, CERNÁ M, ROSSNER P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationaly exposed to cytostatic drugs. Mutat Res 1986; 174:213-217. DOI: https://doi.org/10.1016/0165-7992(86)90154-5
STUCKER 1, HIRSCHA, DOLOYT, BASTIE-SIGEAC 1, HEMON D. Urine mutagenicity chromosomal abnormalities and sister chromatid exchanges in lymphocytes cl nurses handling cytostatic drugs. Int Arch Occup Environ Health 1986; 57: 195-205. DOI: https://doi.org/10.1007/BF00405788
COURTOIS YA, BEAUBESTRE C, BENHAMOU S, MIN S, CALLAIS F, SANCHO-GARNIER H, FESTY B. Détermination delagénotoxicité urinaire: application au dépistage de l'exposition tabagique et/ou professionnelle. Ann Pharm Franc 1987; 45(4): 289-300.
CAUDELL MJ, VREDEVOE DL, DIETRICH MF, CAUDELL TP, HOBAN MJ, BLOK JB. Quantification of urinary mutagens in nurses during potential antineoplastic agent exposure. A pilot study with concurrent environmental and dietary control. Cancer Nurs 1988; 11(1):41-50. DOI: https://doi.org/10.1097/00002820-198802000-00007
ANDERSON RW, PUCKETT. Wft DANA WJ, NGUYEN TU, THEISS JC, MATNEY TS. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982; 39:1881-1887. DOI: https://doi.org/10.1093/ajhp/39.11.1881
NGUYEN TV, THEISS JC, MATNEY TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res 1982; 42: 4792-4796.
LATTSA, SCHRECK RR, LOVEDAY KS, SHULER CF. In vitro and in vivo analysis of sister chromatid exchange. Pharm Reviews 1979; 30: 501-535.
NORPPA H, SORSA M, VAINIO H, GROHN P, HEINONEN E, HOLSTI L, NORDEMAN E. lncreased sister chromatid Exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1980; 6: 299-301. DOI: https://doi.org/10.5271/sjweh.2605
WAKSVII< H, KLEPP O, BROGGER A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat lRep 1981; 65(7-8): 607-6 10.
NIKULA E, KlVlNIITT K, LEISTI J, TASKINEN PJ. Chromosome aberrations in lymphocytes of nurses handling cytostatic agents. Scand J Work Environ Health 1984; 10: 71-74. DOI: https://doi.org/10.5271/sjweh.2355
STILLER A, OBE G, BOLL 1, PRIBILLA W. No elevation of the frequencies of chromosomal alterations as a consequence of handling cytostatic drugs. Analyses with peripheral blood and urine cl hospital personnel. Mutat Res 1983; 121: 253-259. DOI: https://doi.org/10.1016/0165-7992(83)90211-7
JORDAN DK, PATILSR, JOCHIMSEN PR, LACHENBRUCH PA, CORDER MP. Sister chromatid exchange analysis in nurses handling antinoplastic drugs. Cancer lnvest 1986; 4(2): 101-107. DOI: https://doi.org/10.3109/07357908609038253
BENHAMOU S, POT-DEPRUN J, SANCHO-GARNIER H, CHOUROUNLINKOV 1. Sister chromatid exc ires and chromosomal aberrations in lymphocytes of nurses handling cytostatic agents. Int J Cancer 1988; 41: 350-353. DOI: https://doi.org/10.1002/ijc.2910410305
HITCHINGS CR, JENNINGS K, KNASSA, SPEECHLEYV,WHITE A. Guidelines for the handling of cytotoxic drugs. Pharm J 1983; 230-231.
ZIMMERMAN PF, LARSEN RK, BARKLEY EW. Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm 1981;38: 1693-1695. DOI: https://doi.org/10.1093/ajhp/38.11.1693
THOMPSON DF. PVC gloves for handling antineoplastic. Am J Hosp Pharm 1982; 39:227. DOI: https://doi.org/10.1093/ajhp/39.2.227a
NEAL AW, WADDEN RA, CHIOU WL. Exposure cl hospital workers to airborne antineoplastic agents. Am J Hosp Pharm 1983; 40: 597-601. DOI: https://doi.org/10.1093/ajhp/40.4.597
AVIS KE, LEVCHUCK JW. Special considerations in the use of vertical laminar tlow workbenches. Am J Hosp Pha . 1984; 41:81-87. DOI: https://doi.org/10.1093/ajhp/41.1.81
LAIDLAW JL, CONNOR TH, THEISS JC, ANDERSON RW, MATNEY TS. Permeability of latex and polyvinyl chioride gloves to 20 antineopIastic drugs. Am J Hosp Pharm 1984; 41: 2618-2626. DOI: https://doi.org/10.1093/ajhp/41.12.2618
YODAIKEN RE, BENNETT D. OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm 1986; 43: 1193-1204. DOI: https://doi.org/10.1093/ajhp/43.5.1193
HOFFMAN DM. The handling of antineopiastic drugs in a major cancer center. Hosp Pharm 1980; 15:302-304.
WILSONJ JP, SOLIMANDO DA. Aseptic technique as a safety precaution of antineoplastic agents. Hosp Pharm 1981; 16:575-581.
EVANS RM. Guidelines for handling parenteral antineoplastic. JAMA 1985; 253(11): 1590-1592. DOI: https://doi.org/10.1001/jama.253.11.1590
BERG S. Precautions for handling antineoplastic agents in the home. Am J Hosp Pharm 1987; 44:1024. DOI: https://doi.org/10.1093/ajhp/44.5.1024
BACOVSKY R. DsposaI of hazardous pharmaceuticals. Canadian J Hosp Pharm 1981; XXXIV(1): 12-13.
KNOWLES RS, VIRDEN JE. Hand!ing of injectable antineoplastic agents. Br Med J 1980; 281(6240): 589-591. DOI: https://doi.org/10.1136/bmj.281.6240.589
STOLAR MH, POWER LA, VIELE CS. Recommendations for handling cytotoxic drugs in hospitais. Am J Hosp Pharm 1983; 40: 1163-1171. DOI: https://doi.org/10.1093/ajhp/40.7.1163
JOHNSON EG, JANOSIK JE. Manufacture's recommendations for handling spilled antineoplastic agents. Am J Hosp Pharm 1989; 46: 318-3 19. DOI: https://doi.org/10.1093/ajhp/46.2.318
ZELLMER WA. Reducing occupationai exposure to potential carcinogens in hospitais. Am J Hosp Pharm 1981; 38: 1679. DOI: https://doi.org/10.1093/ajhp/38.11.1679
HOY RH, STUMP LM. Etfect of an air-venting filter device an aerossol production from viais. Am J Hosp Pharm 1984; 41:324-326. DOI: https://doi.org/10.1093/ajhp/41.2.324
VENITT S, CROFTON-SLEIGH C, HUNT J, SPEECHLEY V, BRIGGS K. Monitoring exposure of nursing and pharmacy personel to cytotoxic drugs: urinary platinum as markers of absorption. Lancet 1984; 1(8368): 74-77. DOI: https://doi.org/10.1016/S0140-6736(84)90005-9
HARRIS J, DODDS U. Handling waste from patients receiving cytotoxic drugs. Pharm J 1985: 289-291.
COLLS BM. Safety of handling cytotoxic agents: a cause for concern by pharmaceutical companies? Br Med J 1985:291: 1318-1319. DOI: https://doi.org/10.1136/bmj.291.6505.1318
RUBADUE CL. Potential health hazards with antineoplastic drugs. Occup Heaith Nurs 1985; 33: 363-366. DOI: https://doi.org/10.1177/216507998503300707
